Clinical Trials in San Francisco

Showing 5361-5380 of 12,991 trials

Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma

NCT02209376

An Open-Label Phase 1 Pilot Study to determine the safety and feasibility of CART-EGFRvIII (autologous T cells transduced with a lentiviral vector to express a chimeric antigen receptor specific for EGFRvIII) in the treatment of patients with EGFRvIII+ glioblastoma who have had their first recurrence as determined by standard imaging or have have residual disease after initial resection.

Patients With Residual or Reccurent EGFRvIII+ Glioma

University of Pennsylvania11 participantsStarted Nov 2014

San Francisco, California, United States • Philadelphia, Pennsylvania, United States

COMPLETEDPhase 3< 1 mile

Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines

NCT04225260

This is a phase 3, multicenter, open-label study to evaluate the safety of QM1114-DP for the long term treatment of moderate to severe Glabellar (Frown) Lines (GL) and Lateral Canthal Lines (Crow's Feet and LCL).

Glabellar LinesLateral Canthal Lines

Galderma R&D902 participantsStarted Jan 2020

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Fremont, California, United States +27 more locations

Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma

Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines

Find Trials by Condition in San Francisco

Gallium-68 Citrate PET Used in Prostate Cancer

Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma

A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

A Long Term Safety Study of BCX7353 in Hereditary Angioedema

Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib

The Effect of a Brief Online Behavioral Activation Intervention

A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection

Methylphenidate in Treating Patients With Melanoma

Fluorouracil-Uracil and Leucovorin in Treating Elderly Patients With Metastatic Colorectal Cancer

Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer

Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

Treatment of Moderate to Severe Lateral Canthal Lines

Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.

Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer

Mobile Cardiac Telemetry and Advanced Multi-Parameter Monitoring in PatientS Wearing a Novel Device With Biometric Based Medications Changes

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC